Output Biosciences

Output Biosciences

AI-driven preventative therapeutics for chronic disease

Overview

Output Biosciences develops preventative therapeutics to extend human healthspan by combatting chronic diseases. It uses computational biology and AI to discover therapies that can prevent diseases faster, with safer profiles and easier manufacturing, enabling quicker development timelines. The company differentiates itself by integrating biotech expertise with AI to create therapies focused on prevention, and by forming partnerships with pharmaceutical companies, licensing its technologies, and pursuing direct therapy sales. Its goal is to bring preventive treatments to market within months, shifting drug development toward stopping chronic diseases before they start.

YC Company

About Output Biosciences

Simplify's Rating
Why Output Biosciences is rated
D+
Rated D+ on Competitive Edge
Rated C on Growth Potential
Rated D+ on Differentiation

Industries

AI & Machine Learning

Biotechnology

Healthcare

Company Size

1-10

Company Stage

Seed

Total Funding

$130K

Headquarters

New York City, New York

Founded

2020

Simplify Jobs

Simplify's Take

What believers are saying

  • Large Biological Models could accelerate chronic disease prevention across diabetes, heart disease, arthritis.
  • AI-driven drug discovery platform attracts pharma partnerships and licensing revenue opportunities.
  • Team expansion signals commitment to scaling biological reasoning model development and commercialization.

What critics are saying

  • Only $500K raised since 2021 insufficient for capital-intensive biotech model training and trials.
  • Six-person team cannot compete against Recursion, Insitro, Exscientia with 100+ PhDs and billions.
  • FDA's March 2026 AI/ML validation guidelines block IND filings without rigorous preclinical data.

What makes Output Biosciences unique

  • Biologically-aware generative AI architecture designed for nonlinear, high-dimensional biological data.
  • Preventative therapeutics focus enables faster discovery and manufacturing versus traditional drug development.
  • Y Combinator-backed team includes repeat founders, physicians, and computational systems biology researchers.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$130k

Below

Industry Average

Funded Over

1 Rounds

Notable Investors:
Seed funding is usually the first official round after pre-seed, when a startup has a prototype or concept. It’s typically used to develop the product, test the market, and start building the team. Investors here are often angel investors or early-stage venture capitalists.
Seed Funding Comparison
Below Average

Industry standards

$3.3M
$130k
Output Biosciences
$1.5M
Slack
$2M
Netflix
$2.3M
Instacart
$3M
Robinhood

Recently Posted Jobs

Sign up to get curated job recommendations

There are no jobs for Output Biosciences right now.

Find jobs on Simplify and start your career today

We update Output Biosciences's jobs every few hours, so check again soon! Browse all jobs β†’